Basic Information
| LncRNA/CircRNA Name | MIR2052HG |
| Synonyms | NA |
| Region | GRCh38_8:74599775-74823313 |
| Ensemble | ENSG00000254349 |
| Refseq | NR_033830 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | aromatase inhibitor | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | breast cancer |
| ICD-0-3 | C50 |
| Methods | qPCR, Luciferase reporter assay, RIP, Western blot |
| Sample | cell lines(CAMA-1, MCF7/AC1) |
| Expression Pattern | down-regulated |
| Function Description | The cell proliferation and colony formation analysis demonstrated that the cell growth defect caused by downregulation of MIR2052HG could be successfully rescued by LMTK3 overexpression |
| Pubmed ID | 30944027 |
| Year | 2019 |
| Title | The lncRNA MIR2052HG regulates ER? levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1. |
External Links
| Links for MIR2052HG | GenBank HGNC NONCODE |
| Links for breast cancer | OMIM COSMIC |